Titre : Commission d'évaluation du paiement à l'activité (USA)

Commission d'évaluation du paiement à l'activité (USA) : Questions médicales fréquentes

Termes MeSH sélectionnés :

Data Visualization
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Commission d'évaluation du paiement à l'activité (USA) : Questions médicales les plus fréquentes", "headline": "Commission d'évaluation du paiement à l'activité (USA) : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Commission d'évaluation du paiement à l'activité (USA) : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-04-22", "dateModified": "2025-04-17", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Commission d'évaluation du paiement à l'activité (USA)" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Système de paiements préétablis", "url": "https://questionsmedicales.fr/mesh/D011445", "about": { "@type": "MedicalCondition", "name": "Système de paiements préétablis", "code": { "@type": "MedicalCode", "code": "D011445", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "N03.219.521.710.305.200" } } }, "about": { "@type": "MedicalCondition", "name": "Commission d'évaluation du paiement à l'activité (USA)", "alternateName": "Prospective Payment Assessment Commission", "code": { "@type": "MedicalCode", "code": "D011444", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "Patrícia Matos", "url": "https://questionsmedicales.fr/author/Patr%C3%ADcia%20Matos", "affiliation": { "@type": "Organization", "name": "School of Psychology, University of Minho, Campus de Gualtar, 4710-057, Braga, Portugal." } }, { "@type": "Person", "name": "Pedro B Albuquerque", "url": "https://questionsmedicales.fr/author/Pedro%20B%20Albuquerque", "affiliation": { "@type": "Organization", "name": "School of Psychology, University of Minho, Campus de Gualtar, 4710-057, Braga, Portugal." } }, { "@type": "Person", "name": "Jack Tsai", "url": "https://questionsmedicales.fr/author/Jack%20Tsai", "affiliation": { "@type": "Organization", "name": "School of Public Health, The University of Texas Health Science Center at Houston, Houston, Texas, USA Jack.Tsai@uth.tmc.edu." } }, { "@type": "Person", "name": "Jeffrey Pearson", "url": "https://questionsmedicales.fr/author/Jeffrey%20Pearson", "affiliation": { "@type": "Organization", "name": "Arbor Research Collaborative for Health, Ann Arbor, Michigan; and." } }, { "@type": "Person", "name": "Chad Cogan", "url": "https://questionsmedicales.fr/author/Chad%20Cogan", "affiliation": { "@type": "Organization", "name": "Arbor Research Collaborative for Health, Ann Arbor, Michigan; and." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "De-emphasise, Aggregate, and Hide: A Study of Interactive Visual Transformations for Group Structures in Network Visualisations.", "datePublished": "2024-05-09", "url": "https://questionsmedicales.fr/article/38722718", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1109/TVCG.2024.3397785" } }, { "@type": "ScholarlyArticle", "name": "Assessing deep learning reconstruction for faster prostate MRI: visual vs. diagnostic performance metrics.", "datePublished": "2024-05-09", "url": "https://questionsmedicales.fr/article/38724765", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1007/s00330-024-10771-y" } }, { "@type": "ScholarlyArticle", "name": "Integrating Neural-Symbolic Reasoning With Variational Causal Inference Network for Explanatory Visual Question Answering.", "datePublished": "2024-05-08", "url": "https://questionsmedicales.fr/article/38717887", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1109/TPAMI.2024.3398012" } }, { "@type": "ScholarlyArticle", "name": "Self-reported Visual Difficulty, Age-related Eye Disease, and Neuropsychiatric Outcomes in Older Adults.", "datePublished": "2024-05-08", "url": "https://questionsmedicales.fr/article/38718102", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1080/09286586.2024.2343725" } }, { "@type": "ScholarlyArticle", "name": "Evaluation of 3D tablet-based stereoacuity test ASTEROID in children with normal and abnormal visual acuity.", "datePublished": "2024-05-06", "url": "https://questionsmedicales.fr/article/38719139", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.jaapos.2024.103930" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Organisations et économie des soins de santé", "item": "https://questionsmedicales.fr/mesh/D004472" }, { "@type": "ListItem", "position": 3, "name": "Économie", "item": "https://questionsmedicales.fr/mesh/D004467" }, { "@type": "ListItem", "position": 4, "name": "Financement organisé", "item": "https://questionsmedicales.fr/mesh/D005381" }, { "@type": "ListItem", "position": 5, "name": "Remboursement par l'assurance maladie", "item": "https://questionsmedicales.fr/mesh/D007349" }, { "@type": "ListItem", "position": 6, "name": "Mécanismes de remboursement", "item": "https://questionsmedicales.fr/mesh/D012051" }, { "@type": "ListItem", "position": 7, "name": "Système de paiements préétablis", "item": "https://questionsmedicales.fr/mesh/D011445" }, { "@type": "ListItem", "position": 8, "name": "Commission d'évaluation du paiement à l'activité (USA)", "item": "https://questionsmedicales.fr/mesh/D011444" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Commission d'évaluation du paiement à l'activité (USA) - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Commission d'évaluation du paiement à l'activité (USA)", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-05-19", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Commission d'évaluation du paiement à l'activité (USA)", "description": "Quel est le rôle de la Commission ?\nComment la Commission collecte-t-elle des données ?\nQuels types de soins sont évalués ?\nQui compose la Commission ?\nQuels critères sont utilisés pour l'évaluation ?", "url": "https://questionsmedicales.fr/mesh/D011444?mesh_terms=Data+Visualization&page=1000#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Commission d'évaluation du paiement à l'activité (USA)", "description": "Quels problèmes la Commission cherche-t-elle à résoudre ?\nComment la Commission évalue-t-elle l'accès aux soins ?\nQuels indicateurs de performance sont utilisés ?\nComment les résultats sont-ils communiqués ?\nQuels sont les impacts des recommandations de la Commission ?", "url": "https://questionsmedicales.fr/mesh/D011444?mesh_terms=Data+Visualization&page=1000#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Commission d'évaluation du paiement à l'activité (USA)", "description": "Quel est le rôle de la prévention dans l'évaluation ?\nComment la Commission promeut-elle la prévention ?\nQuels types de programmes sont soutenus ?\nComment la prévention impacte-t-elle les coûts ?\nQuels sont les obstacles à la prévention ?", "url": "https://questionsmedicales.fr/mesh/D011444?mesh_terms=Data+Visualization&page=1000#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Commission d'évaluation du paiement à l'activité (USA)", "description": "Comment la Commission influence-t-elle les traitements ?\nQuels traitements sont souvent réévalués ?\nComment les hôpitaux s'adaptent-ils aux recommandations ?\nQuels sont les défis pour les hôpitaux ?\nComment la Commission évalue-t-elle l'efficacité des traitements ?", "url": "https://questionsmedicales.fr/mesh/D011444?mesh_terms=Data+Visualization&page=1000#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Commission d'évaluation du paiement à l'activité (USA)", "description": "Quelles complications sont surveillées par la Commission ?\nComment les complications affectent-elles les paiements ?\nQuels sont les impacts des complications sur les patients ?\nComment la Commission évalue-t-elle les complications ?\nQuelles mesures sont prises pour réduire les complications ?", "url": "https://questionsmedicales.fr/mesh/D011444?mesh_terms=Data+Visualization&page=1000#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Commission d'évaluation du paiement à l'activité (USA)", "description": "Quels facteurs de risque sont pris en compte ?\nComment les facteurs de risque influencent-ils les paiements ?\nQuels outils sont utilisés pour évaluer les risques ?\nComment la Commission aborde-t-elle les inégalités ?\nQuels sont les impacts des facteurs de risque sur les soins ?", "url": "https://questionsmedicales.fr/mesh/D011444?mesh_terms=Data+Visualization&page=1000#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Quel est le rôle de la Commission ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "Elle évalue les systèmes de paiement pour améliorer l'efficacité des soins." } }, { "@type": "Question", "name": "Comment la Commission collecte-t-elle des données ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "Elle utilise des études, des rapports et des données de facturation des hôpitaux." } }, { "@type": "Question", "name": "Quels types de soins sont évalués ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "Tous les soins hospitaliers et ambulatoires sont pris en compte." } }, { "@type": "Question", "name": "Qui compose la Commission ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "Elle est composée d'experts en santé, économistes et représentants des patients." } }, { "@type": "Question", "name": "Quels critères sont utilisés pour l'évaluation ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "Les critères incluent la qualité des soins, les coûts et l'accès aux services." } }, { "@type": "Question", "name": "Quels problèmes la Commission cherche-t-elle à résoudre ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Elle vise à réduire les inégalités d'accès et à améliorer la qualité des soins." } }, { "@type": "Question", "name": "Comment la Commission évalue-t-elle l'accès aux soins ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Elle analyse les données sur l'utilisation des services de santé par les populations." } }, { "@type": "Question", "name": "Quels indicateurs de performance sont utilisés ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "Les indicateurs incluent les taux de réadmission et la satisfaction des patients." } }, { "@type": "Question", "name": "Comment les résultats sont-ils communiqués ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Les résultats sont publiés dans des rapports accessibles au public et aux décideurs." } }, { "@type": "Question", "name": "Quels sont les impacts des recommandations de la Commission ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "Elles influencent les politiques de paiement et les pratiques de soins de santé." } }, { "@type": "Question", "name": "Quel est le rôle de la prévention dans l'évaluation ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "La prévention est essentielle pour réduire les coûts et améliorer la santé publique." } }, { "@type": "Question", "name": "Comment la Commission promeut-elle la prévention ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "Elle recommande des programmes de prévention et des incitations financières." } }, { "@type": "Question", "name": "Quels types de programmes sont soutenus ?", "position": 13, "acceptedAnswer": { "@type": "Answer", "text": "Les programmes de vaccination et de dépistage sont souvent soutenus." } }, { "@type": "Question", "name": "Comment la prévention impacte-t-elle les coûts ?", "position": 14, "acceptedAnswer": { "@type": "Answer", "text": "Une meilleure prévention peut réduire les hospitalisations et les coûts à long terme." } }, { "@type": "Question", "name": "Quels sont les obstacles à la prévention ?", "position": 15, "acceptedAnswer": { "@type": "Answer", "text": "Les obstacles incluent le manque de financement et l'accès limité aux services." } }, { "@type": "Question", "name": "Comment la Commission influence-t-elle les traitements ?", "position": 16, "acceptedAnswer": { "@type": "Answer", "text": "Elle recommande des ajustements de paiement pour encourager des traitements efficaces." } }, { "@type": "Question", "name": "Quels traitements sont souvent réévalués ?", "position": 17, "acceptedAnswer": { "@type": "Answer", "text": "Les traitements coûteux et ceux avec des résultats variables sont souvent réévalués." } }, { "@type": "Question", "name": "Comment les hôpitaux s'adaptent-ils aux recommandations ?", "position": 18, "acceptedAnswer": { "@type": "Answer", "text": "Ils modifient leurs pratiques et protocoles pour répondre aux nouvelles directives." } }, { "@type": "Question", "name": "Quels sont les défis pour les hôpitaux ?", "position": 19, "acceptedAnswer": { "@type": "Answer", "text": "Les hôpitaux doivent équilibrer coûts, qualité des soins et conformité aux recommandations." } }, { "@type": "Question", "name": "Comment la Commission évalue-t-elle l'efficacité des traitements ?", "position": 20, "acceptedAnswer": { "@type": "Answer", "text": "Elle analyse les résultats cliniques et les coûts associés à chaque traitement." } }, { "@type": "Question", "name": "Quelles complications sont surveillées par la Commission ?", "position": 21, "acceptedAnswer": { "@type": "Answer", "text": "Les complications liées aux soins hospitaliers, comme les infections nosocomiales." } }, { "@type": "Question", "name": "Comment les complications affectent-elles les paiements ?", "position": 22, "acceptedAnswer": { "@type": "Answer", "text": "Les complications peuvent entraîner des pénalités financières pour les hôpitaux." } }, { "@type": "Question", "name": "Quels sont les impacts des complications sur les patients ?", "position": 23, "acceptedAnswer": { "@type": "Answer", "text": "Les complications peuvent prolonger l'hospitalisation et affecter la récupération." } }, { "@type": "Question", "name": "Comment la Commission évalue-t-elle les complications ?", "position": 24, "acceptedAnswer": { "@type": "Answer", "text": "Elle analyse les taux de complications et les compare aux normes de soins." } }, { "@type": "Question", "name": "Quelles mesures sont prises pour réduire les complications ?", "position": 25, "acceptedAnswer": { "@type": "Answer", "text": "Des protocoles de soins améliorés et des formations pour le personnel sont mises en place." } }, { "@type": "Question", "name": "Quels facteurs de risque sont pris en compte ?", "position": 26, "acceptedAnswer": { "@type": "Answer", "text": "Les facteurs incluent l'âge, les comorbidités et les conditions socio-économiques." } }, { "@type": "Question", "name": "Comment les facteurs de risque influencent-ils les paiements ?", "position": 27, "acceptedAnswer": { "@type": "Answer", "text": "Les hôpitaux reçoivent des ajustements de paiement basés sur les risques des patients." } }, { "@type": "Question", "name": "Quels outils sont utilisés pour évaluer les risques ?", "position": 28, "acceptedAnswer": { "@type": "Answer", "text": "Des modèles statistiques et des bases de données de santé sont utilisés." } }, { "@type": "Question", "name": "Comment la Commission aborde-t-elle les inégalités ?", "position": 29, "acceptedAnswer": { "@type": "Answer", "text": "Elle analyse les disparités d'accès et de résultats en fonction des facteurs de risque." } }, { "@type": "Question", "name": "Quels sont les impacts des facteurs de risque sur les soins ?", "position": 30, "acceptedAnswer": { "@type": "Answer", "text": "Ils peuvent influencer la qualité des soins et les résultats pour les patients." } } ] } ] }

Sources (10000 au total)

Assessing deep learning reconstruction for faster prostate MRI: visual vs. diagnostic performance metrics.

Deep learning (DL) MRI reconstruction enables fast scan acquisition with good visual quality, but the diagnostic impact is often not assessed because of large reader study requirements. This study use... A retrospective multisite study of 1535 patients assessed biparametric prostate MRI between 2016 and 2020. Likely clinically significant prostate cancer (csPCa) lesions (PI-RADS... DLRecon improved visual quality at 4- and 8-fold (R4, R8) subsampling rates, with SSIM (range: -1 to 1) improved to 0.78 ± 0.02 (p < 0.001) and 0.67 ± 0.03 (p < 0.001) from 0.68 ± 0.03 and 0.51 ± 0.03... DL reconstruction produces visually appealing images but may reduce diagnostic accuracy. Incorporating diagnostic AI into the assessment framework offers a clinically relevant metric essential for ado... In clinical settings, caution is warranted when using DL reconstruction for MRI scans. While it recovered visual quality, it failed to match the prostate cancer detection rates observed in scans not s...

Self-reported Visual Difficulty, Age-related Eye Disease, and Neuropsychiatric Outcomes in Older Adults.

Self-reported visual difficulty is consistently associated with dementia and other neuropsychiatric outcomes, but studies of specific age-related eye diseases have yielded conflicting results.... We conducted a retrospective cohort study using data from The National Health and Aging Trends Study, an ongoing nationally representative survey of older U.S. adults (... Self-reported visual difficulty was associated with dementia (HR 1.16, 95% CI: 1.00-1.34), depression (OR 1.14, 95% CI: 1.04-1.26), anxiety (OR 1.17, 95% CI: 1.06-1.29), and hallucinations (OR 1.54, 9... Self-reported visual difficulty is associated with dementia and other neuropsychiatric outcomes to a greater degree than age-related eye disease. These findings highlight the distinction between self-...

Evaluation of 3D tablet-based stereoacuity test ASTEROID in children with normal and abnormal visual acuity.

To assess the utility of 3D, tablet-based, glasses-free Accurate STEReotest (ASTEROID) in children compared with the Titmus test.... Children aged 5-13 years were enrolled in a single-center, nonrandomized, observational comparison study and analyzed by age (5-7 vs 8-13 years) and visual acuity (20/25 or better in both eyes vs abno... A total of 112 children were included: 28 aged 5-7 with normal visual acuity, 30 aged 5-7 with abnormal visual acuity, 34 aged 8-13 with normal visual acuity, and 20 aged 8-13 with abnormal visual acu... ASTEROID is a digital, tablet-based test that evaluates global stereopsis, does not require glasses, and provides a continuum of scores. Among children, ASTEROID has good agreement with the Titmus tes...

Rate of Initial Optic Nerve Head Capillary Density Loss and Risk of Visual Field Progression.

Rapid initial optic nerve head capillary density loss may be used to assess the risk of glaucoma visual field progression.... To investigate the association between the rate of initial optic nerve head capillary density loss from optical coherence tomography angiography (OCTA) and visual field progression.... This was a retrospective study of a longitudinal cohort at a glaucoma referral center. A total of 167 eyes (96 with primary open-angle glaucoma and 71 with glaucoma suspect) of 109 patients were monit... The rates of initial capillary density and average retinal nerve fiber layer loss were calculated from the first 3 optic nerve head OCTA and OCT scans, respectively, during the initial follow-up (mean... A total of 167 eyes of 109 patients (mean [SD] age, 69.0 [11.1] years; 56 [51.4%] female and 53 [48.6%] male) were assessed. Eighty-three eyes were slow OCTA progressors, while 84 eyes were fast with ... Rapid initial optic nerve head capillary density loss from OCTA was associated with a faster rate of visual field progression and a doubling of the risk of developing event progression in this study. ...

Feasibility of Computerized Visuomotor Integration System for Visual Field Defects and Spatial Neglect in Poststroke Patients.

To develop a computerized visuomotor integration system for assessment and training of visual perception impairments and evaluate its safety and feasibility in patients with a stroke. Visual field def... The CoTras Vision system included two evaluations and four training modules. The evaluation modules were based on the Albert's test and Star cancellation test, and training modules were based on visua... Ten patients with acute stroke completed the study. Bland-Altman plots revealed good agreements for Albert's test (mean difference, -0.3±4.5) and Star cancellation test (mean difference, 0.3±0.7). The... The CoTras Vision system is feasible and safe in patients with stroke. Most patients had a high degree of motivation to use the system and did not experience severe adverse events. Further studies are...

Comparison of vestibular aqueduct visualization on computed tomography and magnetic resonance imaging in patients with Ménière's disease.

The vestibular aqueduct (VA) serves an essential role in homeostasis of the inner ear and pathogenesis of Ménière's disease (MD). The bony VA can be clearly depicted by high-resolution computed tomogr... One hundred patients with unilateral MD underwent MRI with three-dimensional sampling perfection with application optimized contrasts using different flip angle evolutions (3D-SPACE) sequence and HRCT... The most frequent type of MRI-VA and CT-VA visualization was invisible VA and continuous VA, respectively. The MRI-VA visibility was significantly lower than CT-VA visibility. MRI-VA visibility had a ... In patients with MD, the VA visualization on 3D-SPACE MRI is poorer than that observed on CT and may be affected by its osseous configuration. These findings may provide a basis for further characteri...

Visual vertigo and motion sickness is different between persistent postural-perceptual dizziness and vestibular migraine.

Persistent postural-perceptual dizziness (PPPD) and vestibular migraine (VM) share symptoms of visual vertigo and motion sickness that can be confusing for clinicians to distinguish. We compare the se... Twenty-nine patients with PPPD, 37 with VM, and 29 controls were surveyed for subjective symptoms using the visual vertigo analogue scale (VVAS) and motion sickness susceptibility questionnaire during... VVAS revealed contextual differences for dizziness between those with PPPD and VM. Ratings of visual vertigo were most severe in PPPD, less in VM, and mild in controls (VVAS PPPD 27.1, VM 11.2, contro... Patients with PPPD report more visual vertigo than those with VM, but a history of motion sickness as a child is more common in VM. Additionally, the environmental context that induces visual vertigo ...